GSK plc (LSE/NYSE: GSK) announces that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.As previously announced, the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. Under the terms of the agreement, GSK will pay a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.
Read the full article: GSK Completes Acquisition of Aiolos Bio //
Source: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-aiolos-bio